Trial Profile

A Phase 1/2 Multicenter Study of BMS-986012 in Subjects With Relapsed/Refractory Small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 08 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atigotatug (Primary)
Indications Small cell lung cancer
Focus Adverse reactions; First in man
Sponsors Bristol-Myers Squibb

Most Recent Events

06 Feb 2023 Status changed from active, no longer recruiting to completed.
29 Jan 2023 This trial has been completed in Netherlands, according to European Clinical Trials Database record
19 Jan 2023 This trial has been completed in Belgium (End Date: 21 Dec 2022) according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com